Studies
CLN-978-SL-101; CLN-978 for SLE
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Novartis CYTB323L12201; CAR-T for myositis
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
Novartis CYTB323K12201; CAR-T for Scleroderma
Novartis CYTB323J12201; CAR-T for SLE with LN
CAIN457C22301, Secukinumab for PMR
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.
CAIN457R12301 for Giant Cell Arteritis
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)